Onkologie. 2017:11(5):257-262 | DOI: 10.36290/xon.2017.048

News in hormonal therapy for breast cancer

Jan Novotný
Sunderby Hospital, Luleå, Sweden

The present paper deals with the advances in hormone therapy for breast cancer both in post-operative adjuvant indication andin neoadjuvant and palliative indications. The article is aimed at monotherapy with hormonal agents as well as at perspectivecombinations with targeted drugs. Finally the article presents practical advice on how to cope with some adverse treatmenteffects that reduce the quality of life of patients and compliance with treatment.

Keywords: breast cancer, adjuvant therapy, neoadjuvant therapy, palliative therapy, aromatase inhibitors, fulvestrant, cyclin-dependent
kinase inhibitors, mTOR inhibitors, PI3K inhibitors

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novotný J. News in hormonal therapy for breast cancer. Onkologie. 2017;11(5):257-262. doi: 10.36290/xon.2017.048.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dixon JM, Renshaw L, Macaskill EJ, et al. Increase in respons.e rate by prolonged treatment with neoadjuvant letrozole Breast Cancer Res Treat 2009; 113: 145-51. Go to original source... Go to PubMed...
    2. Llombart-Cussac A, Guerrero A, Galan A, et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer Clin Transl Oncol 2012; 14: 125-131. Go to original source... Go to PubMed...
    3. Fontein DB, Charehbili A, Nortier JW, et al. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients-a phase II trial Eur J Cancer 2014; 50: 2190-2200. Go to original source... Go to PubMed...
    4. Carpenter R, Doughty JC, Cordiner C, et al. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery Breast Cancer Res Treat 2014; 144: 569-576. Go to original source... Go to PubMed...
    5. Davies CH, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stoppnig at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet 2013; 381: 805-816. Go to original source... Go to PubMed...
    6. The aTTom collaborative group: long-term effects of continuing adjuvant tamoxifen to 10 years vs. stopping at 5 years in 6953 women with early breast cancer. J clin Oncol 2013; 31(Suppl. 18): Abst 5. Go to original source...
    7. EBCTCG: Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386: 1341-1352. Go to original source... Go to PubMed...
    8. Goss PE, Ingle JN, Pritchard KI, et al. Extended aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 2016; 37: 209-219. Go to original source... Go to PubMed...
    9. Mamounas EP, Bandos H, Lembersky BC, et al. A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant treatment with an aromatas inhibitor. Proc. SABCS 2016; Abst. S1-05. Go to original source...
    10. Tian-Heijen VC, van Hellemond IE, Peer RG, et al. First results from the multicenter phase III DATA study comparing 3 vs. 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer. Proc. SABCS 2016; Abst. S1-03. Go to original source...
    11. Blok EJ, van de Velde CJH, Meershoek-Klein Krannenbarg EM, et al. Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy. Proc. SABCS 2016; Abst. S01-04. Go to original source...
    12. Colleoni M, Luo W, Karlsson P, et al. A phase 3 randomized clinical trial of continuous vs. intermitent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymphnode positive, early breast cancer. Proc. ASCO 2017; Abst. 503. Go to original source...
    13. Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase III trial. Lancet 2016; 388: 2997-3005. Go to original source... Go to PubMed...
    14. Poggio F, Ceppi M, Lambertini M, et al. Concurrent versus sequential adjuvant chemo-endocrine therapy in homone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis. Breast 2017; 33: 104-8. Go to original source... Go to PubMed...
    15. Cardoso F, Villanueva C, Cruz FM, et al. Everolimus plus endocrine therapy in parients with estrogen receptor-positive, HER2-Neu negative advanced breast cancer: first-and second-line data from phase 2 BOLERO-4 study. Proc. ASCO 2017; Abst. 1010. Go to original source...
    16. Xu H, Yu S, Liu Q, et al. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J Hematol Oncol 2017; 10: 97-109. Go to original source... Go to PubMed...
    17. Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progress.ed on endocrine therapy. Proc. ASCO 2017; Abst. 1000. Go to original source...
    18. Cristofanilli M, Turner CN, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor positive, HER2-negative metastatic breast cancer that progress.ed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, dubbel-blind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17: 425-439. Go to original source... Go to PubMed...
    19. Finn SR, Martin M, Rugo HS, et al. Palbociclib and letrozol in advanced breast cancer. N Engl J Med 2016; 375: 1925-36. Go to original source... Go to PubMed...
    20. Hortobagyi GN, Stemmer SN, Burris HA, et al. Ribociclib as first line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016; 375: 1738-1748. Go to original source... Go to PubMed...
    21. Fin SR, Crown J, Lang I, et al. Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs. letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-018). Proc. ASCO 2017; Abst. 1001. Go to original source...
    22. Di Leo A, Seok LK, Ciruelos E, et al. BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment. Proc. SABCS 2016; Abst S4-07. Go to original source...
    23. Baselga J, Im SA, Iwata H, et al. PIK3CA status in circulating tumor DNA predicts efficacy of bupalrisib plus fulvestrant in postmenopausal women with endocrine-resistant HR+/HER2- advanced breast cancer: first results from the randomized, phase III BELLE-2 trial. Proc SABCS 2015; Abst. S6-01. Go to original source...
    24. Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guisdeline. J clin Oncol 2016; 34: 3069-103. Go to original source... Go to PubMed...
    25. Roberts K, Rickett K, Greer R, et al. Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early breast cancer: A systematic review and meta-analysis. Crit Rev in Oncol Hematol 2017; 111: 66-80. Go to original source... Go to PubMed...
    26. Rugo HS, Seneviratne L, Beck JT, et al. Prevention of everolimus-related stomatitis in women with hormone-receptore positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single arm, phase II trial. Lancet Oncol 2017; 18: 654-662. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.